Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients.
Sara N SalernoEdmund V CapparelliHelen McIlleronJacqueline G GerhartJulie B DumondAngela D M KashubaPaolo DentiDaniel GonzalezPublished in: Pharmacotherapy (2022)
Super-boosted LPV/RTV with 15 mg/kg rifampin achieves therapeutic LPV troughs in HIV/TB-infected simulated children.